EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group

Απλή σελίδα τεκμηρίου
dc.contributor.authorDirix, L. Y.en
dc.contributor.authorTonnesen, F.en
dc.contributor.authorCassidy, J.en
dc.contributor.authorEpelbaum, R.en
dc.contributor.authorten Bokkel Huinink, W. W.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorSorio, R.en
dc.contributor.authorGamucci, T.en
dc.contributor.authorWolff, I.en
dc.contributor.authorTe Velde, A.en
dc.contributor.authorLan, J.en
dc.contributor.authorVerweij, J.en
dc.date.accessioned2015-11-24T19:19:04Z
dc.date.available2015-11-24T19:19:04Z
dc.identifier.issn0959-8049-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21925
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Agents/*adverse effects/therapeutic useen
dc.subjectAziridines/*adverse effects/therapeutic useen
dc.subjectBreast Neoplasms/*drug therapyen
dc.subjectColorectal Neoplasms/drug therapyen
dc.subjectDigestive System Neoplasms/*drug therapyen
dc.subjectFemaleen
dc.subjectFollow-Up Studiesen
dc.subjectHumansen
dc.subject*Indolequinonesen
dc.subjectIndoles/*adverse effects/therapeutic useen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPancreatic Neoplasms/drug therapyen
dc.subjectProteinuria/chemically induceden
dc.subjectStomach Neoplasms/drug therapyen
dc.titleEO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Groupen
heal.abstractIn a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8943690-
heal.journalNameEur J Canceren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1996-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ